Private equity's ups and downs: What it means for the life sciences
When it comes to venture capital, higher interest rates aren't necessarily a death sentence, according to columnist Ogan Gurel. In this edition of Med Tech Futures, he contends that higher rates tend to point investors toward higher potential return, higher-risk investments. That means the life...